-
1
-
-
33748998458
-
Pulmonary arterial hypertension
-
McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431.
-
(2006)
Circulation
, vol.114
, pp. 1417-1431
-
-
McLaughlin, V.V.1
McGoon, M.D.2
-
2
-
-
5344233478
-
Pulmonary arterial hypertension
-
Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
-
(2004)
N Engl J Med.
, vol.351
, pp. 1655-1665
-
-
Farber, H.W.1
Loscalzo, J.2
-
3
-
-
0030031888
-
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
-
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
-
(1996)
N Engl J Med.
, vol.334
, pp. 296-301
-
-
Barst, R.J.1
Rubin, L.J.2
Long, W.A.3
McGoon, M.D.4
Rich, S.5
Badesch, D.B.6
Groves, B.M.7
Tapson, V.F.8
Bourge, R.C.9
Brundage, B.H.10
Koerner, S.K.11
Langleben, D.12
Keller, C.A.13
Murali, S.14
Uretsky, B.F.15
Clayton, L.M.16
Jobsis, M.M.17
Blackburn, S.D.18
Shortino, D.19
Crow, J.W.20
more..
-
4
-
-
0037149718
-
Bosentan therapy for pulmonary arterial hypertension
-
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
-
(2002)
N Engl J Med.
, vol.346
, pp. 896-903
-
-
Rubin, L.J.1
Badesch, D.B.2
Barst, R.J.3
Galie, N.4
Black, C.M.5
Keogh, A.6
Pulido, T.7
Frost, A.8
Roux, S.9
Leconte, I.10
Landzberg, M.11
Simonneau, G.12
-
5
-
-
26444534291
-
Sildenafil citrate therapy for pulmonary arterial hypertension
-
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
-
(2005)
N Engl J Med.
, vol.353
, pp. 2148-2157
-
-
Galie, N.1
Ghofrani, H.A.2
Torbicki, A.3
Barst, R.J.4
Rubin, L.J.5
Badesch, D.6
Fleming, T.7
Parpia, T.8
Burgess, G.9
Branzi, A.10
Grimminger, F.11
Kurzyna, M.12
Simonneau, G.13
-
6
-
-
77954758530
-
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
-
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156-163.
-
(2010)
Circulation
, vol.122
, pp. 156-163
-
-
Humbert, M.1
Sitbon, O.2
Chaouat, A.3
Bertocchi, M.4
Habib, G.5
Gressin, V.6
Yaici, A.7
Weitzenblum, E.8
Cordier, J.F.9
Chabot, F.10
Dromer, C.11
Pison, C.12
Reynaud-Gaubert, M.13
Haloun, A.14
Laurent, M.15
Hachulla, E.16
Cottin, V.17
Degano, B.18
Jais, X.19
Montani, D.20
Souza, R.21
Simonneau, G.22
more..
-
7
-
-
84863519076
-
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry
-
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142:448-456.
-
(2012)
Chest
, vol.142
, pp. 448-456
-
-
Benza, R.L.1
Miller, D.P.2
Barst, R.J.3
Badesch, D.B.4
Frost, A.E.5
McGoon, M.D.6
-
8
-
-
84880678637
-
The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload
-
Janssen W, Schermuly RT, Kojonazarov B. The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. Exp Physiol. 2013;98:1274-1278.
-
(2013)
Exp Physiol.
, vol.98
, pp. 1274-1278
-
-
Janssen, W.1
Schermuly, R.T.2
Kojonazarov, B.3
-
9
-
-
79953686516
-
New perspectives for the treatment of pulmonary hypertension
-
Baliga RS, MacAllister RJ, Hobbs AJ. New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol. 2011;163:125-140.
-
(2011)
Br J Pharmacol.
, vol.163
, pp. 125-140
-
-
Baliga, R.S.1
MacAllister, R.J.2
Hobbs, A.J.3
-
10
-
-
54549125950
-
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial
-
Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521-530.
-
(2008)
Ann Intern Med.
, vol.149
, pp. 521-530
-
-
Simonneau, G.1
Rubin, L.J.2
Galie, N.3
Barst, R.J.4
Fleming, T.R.5
Frost, A.E.6
Engel, P.J.7
Kramer, M.R.8
Burgess, G.9
Collings, L.10
Cossons, N.11
Sitbon, O.12
Badesch, D.B.13
-
11
-
-
33748686575
-
Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
-
Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
-
(2006)
Pharmacol Rev.
, vol.58
, pp. 488-520
-
-
Bender, A.T.1
Beavo, J.A.2
-
13
-
-
12244282450
-
Increased expression of the cGMPinhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension
-
Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMPinhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol. 2002;137:1187-1194.
-
(2002)
Br J Pharmacol.
, vol.137
, pp. 1187-1194
-
-
Murray, F.1
MacLean, M.R.2
Pyne, N.J.3
-
14
-
-
0037741441
-
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension
-
Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation. 2003;107:3230-3235.
-
(2003)
Circulation
, vol.107
, pp. 3230-3235
-
-
Sebkhi, A.1
Strange, J.W.2
Phillips, S.C.3
Wharton, J.4
Wilkins, M.R.5
-
15
-
-
33846200014
-
Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: Role for PDE1
-
Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, Yuan JX, Insel PA. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol. 2007;292:L294-L303.
-
(2007)
Am J Physiol.
, vol.292
-
-
Murray, F.1
Patel, H.H.2
Suda, R.Y.3
Zhang, S.4
Thistlethwaite, P.A.5
Yuan, J.X.6
Insel, P.A.7
-
16
-
-
0030733082
-
Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension
-
Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther. 1997;283:619-624.
-
(1997)
J Pharmacol Exp Ther.
, vol.283
, pp. 619-624
-
-
Maclean, M.R.1
Johnston, E.D.2
Mcculloch, K.M.3
Pooley, L.4
Houslay, M.D.5
Sweeney, G.6
-
17
-
-
34247586182
-
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: Target for reverse-remodeling therapy
-
Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A, Klepetko W, Paddenberg R, Kummer W, Seeger W, Grimminger F. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation. 2007;115:2331-2339.
-
(2007)
Circulation
, vol.115
, pp. 2331-2339
-
-
Schermuly, R.T.1
Pullamsetti, S.S.2
Kwapiszewska, G.3
Dumitrascu, R.4
Tian, X.5
Weissmann, N.6
Ghofrani, H.A.7
Kaulen, C.8
Dunkern, T.9
Schudt, C.10
Voswinckel, R.11
Zhou, J.12
Samidurai, A.13
Klepetko, W.14
Paddenberg, R.15
Kummer, W.16
Seeger, W.17
Grimminger, F.18
-
18
-
-
42949113613
-
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition
-
Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS, Savai R, Ghofrani HA, Weissmann N, Schudt C, Flockerzi D, Seeger W, Grimminger F, Schermuly RT. Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur Respir J. 2008;31:599-610.
-
(2008)
Eur Respir J.
, vol.31
, pp. 599-610
-
-
Dony, E.1
Lai, Y.J.2
Dumitrascu, R.3
Pullamsetti, S.S.4
Savai, R.5
Ghofrani, H.A.6
Weissmann, N.7
Schudt, C.8
Flockerzi, D.9
Seeger, W.10
Grimminger, F.11
Schermuly, R.T.12
-
19
-
-
11144258648
-
CAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling
-
Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol. 2005;288:L103-L115.
-
(2005)
Am J Physiol.
, vol.288
-
-
Phillips, P.G.1
Long, L.2
Wilkins, M.R.3
Morrell, N.W.4
-
20
-
-
79954490067
-
Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling
-
Tian X, Vroom C, Ghofrani HA, Weissmann N, Bieniek E, Grimminger F, Seeger W, Schermuly RT, Pullamsetti SS. Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. PLoS One. 2011;6:e18136.
-
(2011)
PLoS One
, vol.6
-
-
Tian, X.1
Vroom, C.2
Ghofrani, H.A.3
Weissmann, N.4
Bieniek, E.5
Grimminger, F.6
Seeger, W.7
Schermuly, R.T.8
Pullamsetti, S.S.9
-
21
-
-
0030712081
-
The GAF domain: An evolutionary link between diverse phototransducing proteins
-
Aravind L, Ponting CP. The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci. 1997;22:458-459.
-
(1997)
Trends Biochem Sci.
, vol.22
, pp. 458-459
-
-
Aravind, L.1
Ponting, C.P.2
-
22
-
-
20944438000
-
Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: Role in endothelial hyperpermeability
-
Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, Hatzelmann A, Tenor H, Schudt C, Krull M, Schutte H, Hippenstiel S, Suttorp N. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood. 2005;105:3569-3576.
-
(2005)
Blood.
, vol.105
, pp. 3569-3576
-
-
Seybold, J.1
Thomas, D.2
Witzenrath, M.3
Boral, S.4
Hocke, A.C.5
Burger, A.6
Hatzelmann, A.7
Tenor, H.8
Schudt, C.9
Krull, M.10
Schutte, H.11
Hippenstiel, S.12
Suttorp, N.13
-
23
-
-
35448930310
-
Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3
-
Surapisitchat J, Jeon KI, Yan C, Beavo JA. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ Res. 2007;101:811-818.
-
(2007)
Circ Res.
, vol.101
, pp. 811-818
-
-
Surapisitchat, J.1
Jeon, K.I.2
Yan, C.3
Beavo, J.A.4
-
24
-
-
0030077686
-
Erythro-9-(2-hydroxy-3-nonyl) adenine inhibits cyclic-3æ, 5æ-guanosine monophosphatestimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung
-
Haynes J Jr, Killilea DW, Peterson PD, Thompson WJ. Erythro-9-(2-hydroxy- 3-nonyl) adenine inhibits cyclic-3æ, 5æ-guanosine monophosphatestimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. J Pharmacol Exp Ther. 1996;276:752-757.
-
(1996)
J Pharmacol Exp Ther.
, vol.276
, pp. 752-757
-
-
Haynes Jr., J.1
Killilea, D.W.2
Peterson, P.D.3
Thompson, W.J.4
-
25
-
-
8844220521
-
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance
-
Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 2004;47:1081-1092.
-
(2004)
Neuropharmacology
, vol.47
, pp. 1081-1092
-
-
Boess, F.G.1
Hendrix, M.2
Van Der Staay, F.J.3
Erb, C.4
Schreiber, R.5
Van Staveren, W.6
De Vente, J.7
Prickaerts, J.8
Blokland, A.9
Koenig, G.10
-
26
-
-
54049141286
-
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension
-
Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, Wilkins MR, MacAllister RJ, Hobbs AJ. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:861-869.
-
(2008)
Am J Respir Crit Care Med.
, vol.178
, pp. 861-869
-
-
Baliga, R.S.1
Zhao, L.2
Madhani, M.3
Lopez-Torondel, B.4
Visintin, C.5
Selwood, D.6
Wilkins, M.R.7
MacAllister, R.J.8
Hobbs, A.J.9
-
27
-
-
0037458096
-
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity
-
Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation. 2003;107:234-237.
-
(2003)
Circulation
, vol.107
, pp. 234-237
-
-
Zhao, L.1
Mason, N.A.2
Strange, J.W.3
Walker, H.4
Wilkins, M.R.5
-
28
-
-
84862125705
-
Dietary nitrate ameliorates pulmonary hypertension: Cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase
-
Baliga RS, Milsom AB, Ghosh SM, Trinder SL, Macallister RJ, Ahluwalia A, Hobbs AJ. Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation. 2012;125:2922-2932.
-
(2012)
Circulation
, vol.125
, pp. 2922-2932
-
-
Baliga, R.S.1
Milsom, A.B.2
Ghosh, S.M.3
Trinder, S.L.4
Macallister, R.J.5
Ahluwalia, A.6
Hobbs, A.J.7
-
29
-
-
78349278479
-
Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension
-
Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182:1161-1170.
-
(2010)
Am J Respir Crit Care Med.
, vol.182
, pp. 1161-1170
-
-
Falcetti, E.1
Hall, S.M.2
Phillips, P.G.3
Patel, J.4
Morrell, N.W.5
Haworth, S.G.6
Clapp, L.H.7
-
30
-
-
84862218009
-
Contributions of nitric oxide synthases, dietary nitrite/nitrate, and other sources to the formation of NO signaling products
-
Milsom AB, Fernandez BO, Garcia-Saura MF, Rodriguez J, Feelisch M. Contributions of nitric oxide synthases, dietary nitrite/nitrate, and other sources to the formation of NO signaling products. Antioxid Redox Signal. 2012;17:422-432.
-
(2012)
Antioxid Redox Signal
, vol.17
, pp. 422-432
-
-
Milsom, A.B.1
Fernandez, B.O.2
Garcia-Saura, M.F.3
Rodriguez, J.4
Feelisch, M.5
-
31
-
-
20444397009
-
Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice
-
Bubikat A, De Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, Godecke A, Baba HA, Kuhn M. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem. 2005;280:21594-21599.
-
(2005)
J Biol Chem.
, vol.280
, pp. 21594-21599
-
-
Bubikat, A.1
De Windt, L.J.2
Zetsche, B.3
Fabritz, L.4
Sickler, H.5
Eckardt, D.6
Godecke, A.7
Baba, H.A.8
Kuhn, M.9
-
32
-
-
0024282457
-
Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide
-
Kenny AJ, Stephenson SL. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 1988;232:1-8.
-
(1988)
FEBS Lett.
, vol.232
, pp. 1-8
-
-
Kenny, A.J.1
Stephenson, S.L.2
-
33
-
-
84880721470
-
Riociguat for the treatment of pulmonary arterial hypertension
-
Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330-340.
-
(2013)
N Engl J Med.
, vol.369
, pp. 330-340
-
-
Ghofrani, H.A.1
Galie, N.2
Grimminger, F.3
Grunig, E.4
Humbert, M.5
Jing, Z.C.6
Keogh, A.M.7
Langleben, D.8
Kilama, M.O.9
Fritsch, A.10
Neuser, D.11
Rubin, L.J.12
-
34
-
-
0042859823
-
Cyclic GMP phosphodiesterases and regulation of smooth muscle function
-
Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93:280-291.
-
(2003)
Circ Res.
, vol.93
, pp. 280-291
-
-
Rybalkin, S.D.1
Yan, C.2
Bornfeldt, K.E.3
Beavo, J.A.4
-
35
-
-
33646795266
-
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
-
Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation. 2006;113:2221-2228.
-
(2006)
Circulation
, vol.113
, pp. 2221-2228
-
-
Castro, L.R.1
Verde, I.2
Cooper, D.M.3
Fischmeister, R.4
-
36
-
-
33644865929
-
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway
-
Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006;98:226-234.
-
(2006)
Circ Res.
, vol.98
, pp. 226-234
-
-
Mongillo, M.1
Tocchetti, C.G.2
Terrin, A.3
Lissandron, V.4
Cheung, Y.F.5
Dostmann, W.R.6
Pozzan, T.7
Kass, D.A.8
Paolocci, N.9
Houslay, M.D.10
Zaccolo, M.11
-
37
-
-
70049112901
-
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
-
Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
-
(2009)
Eur Heart J.
, vol.30
, pp. 2493-2537
-
-
Galie, N.1
Hoeper, M.M.2
Humbert, M.3
Torbicki, A.4
Vachiery, J.L.5
Barbera, J.A.6
Beghetti, M.7
Corris, P.8
Gaine, S.9
Gibbs, J.S.10
Gomez-Sanchez, M.A.11
Jondeau, G.12
Klepetko, W.13
Opitz, C.14
Peacock, A.15
Rubin, L.16
Zellweger, M.17
Simonneau, G.18
-
38
-
-
84899974051
-
Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium [published online ahead of print January 15, 2014]
-
DOI:10.1007/s00210-013-0953-1
-
Moltzau LR, Meier S, Aronsen JM, Afzal F, Sjaastad I, Skomedal T, Osnes JB, Levy FO, Qvigstad E. Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium [published online ahead of print January 15, 2014]. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:407-417. DOI:10.1007/s00210-013-0953-1.
-
(2014)
Naunyn Schmiedebergs Arch Pharmacol.
, vol.387
, pp. 407-417
-
-
Moltzau, L.R.1
Meier, S.2
Aronsen, J.M.3
Afzal, F.4
Sjaastad, I.5
Skomedal, T.6
Osnes, J.B.7
Levy, F.O.8
Qvigstad, E.9
-
39
-
-
84886059882
-
Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes
-
Mehel H, Emons J, Vettel C, Wittkopper K, Seppelt D, Dewenter M, Lutz S, Sossalla S, Maier LS, Lechene P, Leroy J, Lefebvre F, Varin A, Eschenhagen T, Nattel S, Dobrev D, Zimmermann WH, Nikolaev VO, Vandecasteele G, Fischmeister R, El-Armouche A. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol. 2013;62:1596-1606.
-
(2013)
J Am Coll Cardiol.
, vol.62
, pp. 1596-1606
-
-
Mehel, H.1
Emons, J.2
Vettel, C.3
Wittkopper, K.4
Seppelt, D.5
Dewenter, M.6
Lutz, S.7
Sossalla, S.8
Maier, L.S.9
Lechene, P.10
Leroy, J.11
Lefebvre, F.12
Varin, A.13
Eschenhagen, T.14
Nattel, S.15
Dobrev, D.16
Zimmermann, W.H.17
Nikolaev, V.O.18
Vandecasteele, G.19
Fischmeister, R.20
El-Armouche, A.21
more..
-
40
-
-
0032814621
-
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
-
O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(pt 1):78-86.
-
(1999)
Am Heart J.
, vol.138
, Issue.PART 1
, pp. 78-86
-
-
O'Connor, C.M.1
Gattis, W.A.2
Uretsky, B.F.3
Adams Jr., K.F.4
McNulty, S.E.5
Grossman, S.H.6
McKenna, W.J.7
Zannad, F.8
Swedberg, K.9
Gheorghiade, M.10
Califf, R.M.11
-
41
-
-
0026072848
-
Effect of oral milrinone on mortality in severe chronic heart failure
-
PROMISE Study Research Group
-
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML; the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
-
(1991)
N Engl J Med.
, vol.325
, pp. 1468-1475
-
-
Packer, M.1
Carver, J.R.2
Rodeheffer, R.J.3
Ivanhoe, R.J.4
DiBianco, R.5
Zeldis, S.M.6
Hendrix, G.H.7
Bommer, W.J.8
Elkayam, U.9
Kukin, M.L.10
-
42
-
-
34247333783
-
How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension
-
Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med. 2007;175:846-850.
-
(2007)
Am J Respir Crit Care Med.
, vol.175
, pp. 846-850
-
-
Kerbaul, F.1
Brimioulle, S.2
Rondelet, B.3
Dewachter, C.4
Hubloue, I.5
Naeije, R.6
-
43
-
-
77957694135
-
Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats
-
Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, Voelkel NF. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med. 2010;182:652-660.
-
(2010)
Am J Respir Crit Care Med.
, vol.182
, pp. 652-660
-
-
Bogaard, H.J.1
Natarajan, R.2
Mizuno, S.3
Abbate, A.4
Chang, P.J.5
Chau, V.Q.6
Hoke, N.N.7
Kraskauskas, D.8
Kasper, M.9
Salloum, F.N.10
Voelkel, N.F.11
-
44
-
-
84859628413
-
Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension
-
de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail. 2012;5:97-105.
-
(2012)
Circ Heart Fail.
, vol.5
, pp. 97-105
-
-
De Man, F.S.1
Handoko, M.L.2
Van Ballegoij, J.J.3
Schalij, I.4
Bogaards, S.J.5
Postmus, P.E.6
Van Der Velden, J.7
Westerhof, N.8
Paulus, W.J.9
Vonk-Noordegraaf, A.10
|